Latest Matuzumab Stories
COPENHAGEN, Denmark, September 6, 2012 /PRNewswire/ -- - Symphogen Will Host a Conference Call Today (Thursday 6 September 2012) to Discuss the Announcement at 11:30 CET/ 10:30 BST, Details on How Access This Call and the Accompanying Presentation are Below. - A novel investigational antibody mixture targeting the epidermal growth factor receptor (EGFR) Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of...
LUX-Lung 3 trial results highlighted at the official ASCO Press Conference: Afatinib* delays lung cancer progression compared to standard chemotherapy BURLINGTON, ON, June 4, 2012 /CNW/ - The LUX-Lung 3 Phase III results showed that lung cancer patients taking the novel compound afatinib*, an irreversible ErbB Family Blocker, as a first-line treatment, lived for almost one year before their disease progressed (progression-free survival (PFS) of 11.1 months) versus just over half...
MISSISSAUGA, ON, Sept. 26, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a drug development company advancing a diverse portfolio of hematology and cancer-related products, today announced that data from several clinical trials of nimotuzumab are scheduled be reported at the 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011, in Stockholm, Sweden. A poster presentation entitled "Phase 2 study of nimotuzumab in combination with...
CALGARY, July 6, 2011 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics") today announced that a presentation covering interim preliminary results from a Phase 2 clinical trial using intravenous administration of REOLYSIN(® )in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumours was made today at the International Association for the Study of Lung Cancer World Conference on...
EXTON, Pa., June 28, 2011 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center phase II study of farletuzumab in adenocarcinoma of the lung, a type of non-small cell lung cancer (NSCLC). The study will evaluate farletuzumab, a monoclonal antibody that specifically binds to folate receptor-alpha (FRA), with the physician's choice of one of three standard platinum-containing doublets that are approved and recommended for...
CALGARY, June 8, 2011 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC), (NASDAQ:ONCY) ("Oncolytics") today announced that an abstract covering interim preliminary results from a Phase 2 clinical trial using intravenous administration of REOLYSIN(® )in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumours is available on the International Association for the Study of Lung Cancer World Conference on Lung...
MISSISSAUGA, ON, Jan. 20 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a life sciences product development company advancing a diverse portfolio of promising hematology and cancer-related products at various stages of development, today announced that results were reported from a randomized Phase II gastric cancer study of nimotuzumab being conducted by its licensees, Daiichi Sankyo Co., Ltd. in Japan and Kuhnil Pharma Co. Ltd., in Korea. "The overall findings of the study...
Large, global phase IV study extends therapy benefits beyond standard patient populationFeatured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population.Erlotinib has been shown...
African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib."This study has immediate implications for patient management. Patients with EGFR mutations have a much better prognosis and respond better to erlotinib than those who do not," said Ramsi Haddad, Ph.D., director of the Laboratory of...
BROOMFIELD, Colo., April 19 /PRNewswire/ -- Biodesix today announced that results from the VeriStrat biomarker analysis of a Phase III clinical trial will be presented by David Carbone, M.D., Ph.D., Professor of Medicine and Cancer Biology, Vanderbilt University School of Medicine, on Friday, April 30th at the 2nd European Lung Cancer Conference to be held in Geneva, Switzerland. The purpose of the study was to evaluate the ability of VeriStrat to predict patient outcomes to epidermal...
